Epicrispr raises $90.0M (Aug 2026)
Find the investors funding Health rounds
326,000+ verified VCs, angels and family offices — direct emails, check sizes and stage filters.
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease - BioPharma Dive
Epicrispr is focused on developing epigenetic editing therapies for rare muscle diseases. The company aims to leverage its innovative technology to address unmet medical needs in this niche market. The recent funding will help advance their drug development efforts.
Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease BioPharma Dive
| Sep 02, 2026 | Thyme Care | $125.0M | Series E | United States |
| Sep 02, 2026 | DocPharma | $2.0M | Pre-Series A | India |
| Sep 02, 2026 | GonGlobal | $1.2M | Seed | Australia |
| Sep 01, 2026 | Norbert Health | $14.0M | Series A | United States |
Find the investors behind rounds like this one
You just read who funded Epicrispr. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 5 investor contact unlocks a month, no card required.